CPIX - カンバ―ランド・ファ―マシュ―ティカルズ （Cumberland Pharmaceuticals Inc.）

NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023. A…

WILMINGTON, DE / ACCESSWIRE / March 31, 2023 / Transparency Market Research Inc. - The global vasopressin antagonists market stood at USD 1.7 Bn in 2022 and the global market is projected to reach USD 2.7 Bn by 2031. The global industry is anticipated to expand at a CAGR of 4.9% between 2023 and 2031. Hyponatremia is a common electrolyte disorder that affects millions of people worldwide. The rising prevalence of hyponatremia is expected to drive the demand for vasopressin antagonists, as they are the primary treatment option for this condition. Request for a Sample PDF Report with Insights, Charts, Tables, and Figures at https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85509 Market Snapshot: Report Coverage Details Market Revenue USD 1.7 Bn in 2022 Estimated Value USD 2.7 Bn by 2031 Growth Rate 4.9% Forecast Period 2023-2031 No. of Pages 183 Pages Market Segmentation By Drug Type, Application and Distribution Channel Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, South America Companies Covered Otsuka, Cumberland Pharmaceuticals, Mayo Clinic, and Hopital du Sacre-Coeur de Montreal The market value of the vasopressin antagonists is also increasing due to the growing incidence of heart failure.

Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ETCompany ParticipantsMolly Aggas - Account Supervisor, Dalton AgencyA.J.

NASHVILLE, Tenn. (AP) — NASHVILLE, Tenn. (AP) — Cumberland Pharmaceuticals Inc. (CPIX) on Tuesday reported a loss of $2.4 million…

Cumberland Pharmaceuticals press release (NASDAQ:CPIX): FY GAAP EPS of -$0.17.Revenue of $9.12M (+9.9% Y/Y).

NASHVILLE, Tenn., Nov. 1, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its third quarter 2022 financial results and provide a company update after the market closes on Tuesday, Nov. 8, 2022. A…

Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J.

NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022….

Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q1 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency…

The following slide deck was published by Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q2 2022 Results Conference Call August 9, 2022 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J.

NASHVILLE, Tenn., Aug. 2, 2022 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2022 financial results and provide a company update after the market closes on Tuesday, Aug. 9, 2022….

Cumberland Pharmaceuticals Inc. (NASDAQ:NASDAQ:CPIX) Q1 2022 Results Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency…

The following slide deck was published by Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals press release (CPIX): Q1 Non-GAAP EPS of $0.03.Revenue of $11.2M (+6.3% Y/Y).Shares +1.95% AH.